Viewing Study NCT04743154



Ignite Creation Date: 2024-05-06 @ 3:45 PM
Last Modification Date: 2024-10-26 @ 1:56 PM
Study NCT ID: NCT04743154
Status: COMPLETED
Last Update Posted: 2023-04-24
First Post: 2021-02-03

Brief Title: In-hospital Versus After-discharge Complete Revascularization
Sponsor: Hospital General Universitario de Valencia
Organization: Hospital General Universitario de Valencia

Study Overview

Official Title: In-hospital Versus After-discharge Complete Revascularization in STEMI Patients With Multivessel Disease
Status: COMPLETED
Status Verified Date: 2023-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: REVIVA-ST
Brief Summary: Patients with STEMI and multivessel disease in whom the culprit lesion has been successfully revascularized during prmimary PCI will be randomized to in-hospital or after-discharge complete revascularization

The purpose of this study is to evaluate the impact of these two different strategies in terms of hospital stay
Detailed Description: STEMI patients with mutivessel disease are after successful primary angioplasty randomized 11 ratio to either in-hospital complete revascularization or after-discharge complete revascularization strategy

Eligible non-culprit coronary arteries must be 20 mm in diameter and at the discretion of the operator suitable for PCI Only arteries with angiographically stenoses 70 or between 50 and 70 in proximal segments can be randomized

Patients in the in-hospital revascularization group will undergo to non-culprit percutaneous coronary intervention PCI at least 24 hours after ST-segment elevation myocardial infarction On the other hand patients in the after-discharge group will undergo to non-culprit PCI within 4-6 weeks after STEMI

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None